MINT-RIVASTIGMINE CAPSULE
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
22-12-2016
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
제공처:
MINT PHARMACEUTICALS INC
ATC 코드:
N06DA03
INN (International Name):
RIVASTIGMINE
복용량:
4.5MG
약제 형태:
CAPSULE
구성:
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5MG
관리 경로:
ORAL
패키지 단위:
56/100
처방전 유형:
Prescription
치료 영역:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
제품 요약:
Active ingredient group (AIG) number: 0140521003; AHFS:
승인 상태:
CANCELLED POST MARKET
승인 날짜:
2017-06-19
제품 특성 요약
PRODUCT MONOGRAPH
PR
MINT-RIVASTIGMINE
1.5 mg, 3 mg, 4.5 mg, 6 mg Rivastigmine
(supplied as Rivastigmine Hydrogen Tartrate)
Capsules
Mint Standard
Cholinesterase Inhibitor
Mint Pharmaceuticals Inc. Date of Revision: December 22, 2016
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
Submission Control No: 200803
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
............................................................................
3
CONTRAINDICATIONS
..............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
............................................................................................
11
DRUG INTERACTIONS
............................................................................................
25
DOSAGE AND ADMINISTRATION
...........................................................................
26
OVERDOSAGE
.........................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 29
STORAGE AND STABILITY
......................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 32
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
PHARMACEUTICAL INFORMATION
........................................................................
33
CLINICAL TRIALS
.....................................................................................................
34
DETAILED PHARMACOLOGY
..........................................................................
전체 문서 읽기
